Moreover, chromatin immunoprecipitation (ChIP) assay results showed that HBXIP bound to the MEK2 promoter, but not that of MEK1 or MEK3 in breast cancer cells, suggesting that HBXIP may activate ERK1/2 by promoting MEK2 expression. This evidence concerns the gene MAP2K3 and breast carcinoma.